Russian Antimonopoly Service Flags Unfair Competition in Apixaban Generics Launch

Russia's FAS has preliminarily identified signs of unfair competition in the market introduction of two apixaban generics, 'Apixanta' and 'Apiclis', following a complaint from Pfizer Innovations and the patent holder. The finding is preliminary and subject to further review; it signals potential regulatory friction for generic entrants in the Russian pharmaceutical market.